CIRM Funded Clinical Trials

GENE-MODIFIED HEMATOPOIETIC STEM/PROGENITOR CELL BASED THERAPY FOR HIV DISEASE


Geoff Symonds
Disease Area: 
Investigator:
Institution:
CIRM Grant:
Award Value:
$8,278,722
Trial Sponsor:
Trial Stage: 
Phase 1/2
Trial Status: 
Active, not recruiting
Targeted Enrollment:
12
ClinicalTrials.gov ID:
Details: 

Cal-1 increases the number of HIV-protected cells in the body. Uses shRNA to CCR5 and C46 to confer cellular resistance to HIV infection.

Design: 

Single arm, non-randomised study.

Goal: 

Safety. Efficacy - slow disease progression, mitigate need for ART.

Status: 

Enrolled and treated 10 patients. Evidence of safety and feasibility.